Journal of Hepatology
Volume 49, Issue 3 , Pages 339-345 , September 2008

Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection

  • Juliane Halangk

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • Corresponding Author InformationCorresponding authors. Tel.: +49 30 450 553072; fax: +49 30 450 553903.
    • Medizinische Klinik I, Markus-Krankenhaus, Frankfurt/Main, Germany.
    • ,
  • Christoph Sarrazin

      Affiliations

    • Medizinische Klinik I, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt/Main, Germany
    • ,
  • Konrad Neumann

      Affiliations

    • Institut für Biometrie und Klinische Epidemiologie, Charité Universitätsmedizin Berlin, Campus Mitte, Germany
    • ,
  • Gero Puhl

      Affiliations

    • Klinik für Allgemein, Viszeral und Transplantationschirurgie, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Tobias Mueller

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Gerlinde Teuber

      Affiliations

    • Medizinische Klinik I, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt/Main, Germany
    • ,
  • Hartwig Klinker

      Affiliations

    • Medizinische Klinik und Poliklinik II, Universität Würzburg, Germany
    • ,
  • Holger Hinrichsen

      Affiliations

    • Gemeinschaftspraxis für Innere Medizin, Kiel, Germany
    • ,
  • Peter Buggisch

      Affiliations

    • I. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Germany
    • ,
  • Olfert Landt

      Affiliations

    • TIB MOLBIOL, Berlin, Germany
    • ,
  • Viola Weich

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Alexandra Bergk

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Bertram Wiedenmann

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Peter Neuhaus

      Affiliations

    • Klinik für Allgemein, Viszeral und Transplantationschirurgie, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • ,
  • Thomas Berg

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • Corresponding Author InformationCorresponding authors. Tel.: +49 30 450 553072; fax: +49 30 450 553903.
    • Authors contributed equally to this work and share senior and corresponding authorship.
    • ,
  • Heiko Witt

      Affiliations

    • Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany
    • Authors contributed equally to this work and share senior and corresponding authorship.

Received 14 December 2007 ,Revised 24 April 2008 ,Accepted 27 May 2008.

References 

  1. Cohen J. The scientific challenge of hepatitis C. Science. 1999;285:26–30
  2. Feld JJ, Liang TJ. Hepatitis C – identifying patients with progressive liver injury. Hepatology. 2006;43:194–206
  3. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687–1695
  4. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. J Hepatol. 2005;43:590–598
  5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832
  6. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–265
  7. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451–455
  8. Collier JD, Woodall T, Wight DG, Shore S, Gimson AE, Alexander GJ. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat. 2005;12:74–80
  9. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003;37:493–503
  10. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology. 2003;125:1085–1093
  11. Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003;38:1468–1476
  12. Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55:269–362
  13. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology. 1998;27:1695–1699
  14. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828–833
  15. Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, Zavaglia C, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology. 2002;36:195–201
  16. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Trent HCV Study Group. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology. 2002;36:456–463
  17. Glas J, Torok HP, Tonenchi L, Schiemann U, Folwaczny C. The −2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology. 2004;126:1930–1931
  18. Bonkovsky HL, Salek J. No role of the −2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. Gastroenterology. 2005;129:1361–1362
  19. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut. 2002;50:248–252
  20. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005;37:835–843
  21. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140–1144
  22. Schieferdecker HL, Schlaf G, Jungermann K, Gotze O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol. 2001;1:469–481
  23. Czermak BJ, Lentsch AB, Bless NM, Schmal H, Friedl HP, Ward PA. Role of complement in in vitro and in vivo lung inflammatory reactions. J Leukoc Biol. 1998;64:40–48
  24. Sheerin NS, Sacks SH. Leaked protein and interstitial damage in the kidney: is complement the missing link?. Clin Exp Immunol. 2002;130:1–3
  25. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374
  26. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526
  27. Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology. 2004;39:1456–1457
  28. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376–1382
  29. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282–292
  30. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol. 2006;41:209–224
  31. Thursz M. Pros and cons of genetic association studies in hepatitis B. Hepatology. 2004;40:284–286
  32. Donaldson PT. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol. 2004;41:327–332

☆ Dr. Landt is employed by TIB MOLBIOL, Berlin, Germany. The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00371-1

doi: 10.1016/j.jhep.2008.05.021

Journal of Hepatology
Volume 49, Issue 3 , Pages 339-345 , September 2008

Article Tools